Table 1.
Cytotoxic activity of lapachol-containing ruthenium complexes.
| IC50 [µM] | |||||
|---|---|---|---|---|---|
| DXR | CIS | (1) | (2) | Lp | |
| Cancer cells | |||||
| A-375 | 3.7 ± 0.6 | 16.5 ± 2.3 | 2.5 ± 0.6 | 0.9 ± 0.3 | >100.0 |
| A549 | 1.9 ± 0.4 | 11.9 ± 0.6 | 3.3 ± 0.4 | 2.6 ± 0.1 | >100.0 |
| Caco-2 | 2.1 ± 0.8 | 17.4 ± 0.3 | 2.0 ± 0.6 | 1.2 ± 0.3 | >100.0 |
| DU-145 | 2.3 ± 0.5 | 24.3 ± 1.3 | 0.9 ± 0.2 | 0.8 ± 0.1 | >100.0 |
| HepG2 | 2.4 ± 0.8 | 14.1 ± 0.5 | 1.7 ± 0.5 | 1.5 ± 0.2 | >100.0 |
| MDA-MB-231 | 2.1 ± 0.7 | 22.1 ± 1.7 | 2.1 ± 0.4 | 2.0 ± 0.0 | >100.0 |
| PC-3 | 2.6 ± 0.3 | 10.8 ± 1.1 | 1.3 ± 0.4 | 1.1 ± 0.3 | >100.0 |
| Non-cancer cells | |||||
| FGH | 2.6 ± 0.6 | 11.4 ± 0.5 | 3.1 ± 0.2 | 2.5 ± 0.3 | >100.0 |
| PNT-2 | 3.2 ± 0.5 | 9.5 ± 0.3 | 5.9 ± 2.1 | 6.8 ± 1.5 | >100.0 |
Data are presented as the means ± S.E.M. of IC50 values in μM obtained by nonlinear regression from at the least three independent experiments performed in triplicate, measured by Alamar blue® assay after 24-h incubation. Cancer cells: A-375 (human malignant melanoma); A549 (human lung carcinoma); Caco-2 (human colorectal adenocarcinoma); DU-145 (human prostate adenocarcinoma); HepG2 (human hepatocellular carcinoma); MDA-MB-231 (human breast adenocarcinoma) and PC-3 (human prostate adenocarcinoma). Non-cancer cells: FGH (human mouth fibroblast) and PNT-2 (human prostate epithelial cells). Cisplatin (CIS), doxorubicin (DXR) and lapachol (Lp) were used as controls.